(Q34232307)

31 July 2017

1 reference

title

Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans (English)

1 reference

31 July 2017

Bar-Tana J

1

1 reference

31 July 2017

1 March 2001

1 reference

31 July 2017

1 reference

31 July 2017

120

1 reference

31 July 2017

9-19

1 reference

31 July 2017

1-3

1 reference

Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Efficacy of troglitazone on body fat distribution in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Troglitazone action is independent of adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Peroxisome proliferator-activated receptors: nuclear control of metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

1 reference

7 January 2021

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Effect of troglitazone on body fat distribution in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Terminal differentiation of human breast cancer through PPAR gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Transcriptional control of adipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Differentiation and reversal of malignant changes in colon cancer through PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2801%2900302-2

7 January 2021

10.1016/S0378-4274(01)00302-2

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11323157